title: Protease inhibition as new therapeutic strategy for GI diseases.
abstract: The GI tract is the most exposed organ to proteases, both in physiological and pathophysiological conditions. For digestive purposes, the lumen of the upper GI tract contains large amounts of pancreatic proteases, but studies have also demonstrated increased proteolytic activity into mucosal tissues (both in the upper and lower GI tract), associated with pathological conditions. This review aims at outlining the evidences for dysregulated proteolytic homeostasis in GI diseases and the pathogenic mechanisms of increased proteolytic activity. The therapeutic potential of protease inhibition in GI diseases is discussed, with a particular focus on IBDs, functional GI disorders and colorectal cancer.
authors.affiliation: Inserm, U1220, Toulouse, France Université de Toulouse, Université Paul Sabatier, Institut de Recherche en Santé Digestive (IRSD), Toulouse, France Inra, U1416, Toulouse, France Ecole Nationale Vétérinaire de Toulouse (ENVT), France Department of Pharmacology and Physiology, University of Calgary, Calgary, Alberta, Canada.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Vergnolle
mesh_terms: D000818:Animals; D002446:Celiac Disease / Q000188:drug therapy; D015179:Colorectal Neoplasms / Q000188:drug therapy; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000201:enzymology*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D010447:Peptide Hydrolases / Q000502:physiology*; D011480:Protease Inhibitors / Q000627:therapeutic use*
chemical_list: D011480:Protease Inhibitors; D010447:Peptide Hydrolases
keywords: ENZYMOLOGY; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY BOWEL SYNDROME; INFLAMMATORY MECHANISMS